FTC v. Abbvie involved litigation about a patent for a “blockbuster testosterone replacement therapy.” The 3rd Circuit held that the District Court erred by rejecting the FTC’s reverse-payment theory and in concluding that the defendants’ patent infringement litigation was a sham.
